We have set up this channel to give you convenient access to the latest research in the area of Cancer-associated thrombosis (CAT) by providing a customised feed of abstracts of clinical papers published on PubMed. The combination of search terms providing the feed below is 'cancer AND thrombosis'. This channel is sorted chronologically. To see more information about a given paper, click the ‘Preview Abstract’ button below, and this will reveal an expanded abstract.
Direct oral anticoagulants (DOACs) represent an attractive alternative to low-molecular-weight heparins (LMWHs) for the long-term treatment of cancer-associated thrombosis (CT) since they avoid the burden of daily injections. Analyses in subgroups of cancer patients from large randomized trials suggested that DOACs were at least as effective as vitamin K antagonists, while indirect comparisons suggested that DOACs' efficacy and safety profile were comparable to those of...
BACKGROUND: Patients with acute pulmonary embolism (PE) often have leg deep vein thrombosis (DVT); sometimes, however, a DVT is not detected (isolated PE, I-PE). We aimed at assessing the proportion of patients with I-PE, and their characteristics and clinical evolution compared to those with DVT with/without PE (DVT/PE).
METHODS: Among 3573 patients included in the START2-Register for a venous thromboembolic event, 2880 (80.6%) had DVT/PE, the remaining I-PE...
BACKGROUND: The thrombodynamic test (TD) is a novel global test of hemostasis that allows to study the spatial-temporal characteristics of a clot formation in real time under conditions close to natural ones and demonstrates high sensitivity to detect the state of hypercoagulation. The main paraments of the test are the velocity of clot growth, clot's size, and clot density. The objective of this study was to compare the classic Caprini 2005 score and its modified version in...
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at a high risk of VTE recurrence and bleeding during anticoagulant therapy. The International Initiative on Thrombosis and Cancer is an independent academic working group aimed at establishing a global consensus for the treatment and prophylaxis of VTE in patients with cancer. The International Initiative on Thrombosis and Cancer last updated its evidence-based...
Acutely ill medical patients with cancer are at increased risk of venous thromboembolism (VTE). Thromboprophylaxis is recommended in the presence of cancer, but its safety is not known. The aim of this study was to assess the efficacy and safety of extended prophylaxis with betrixaban in cancer patients enrolled in the APEX trial. APEX was a randomized, double-blind trial comparing oral betrixaban 80 mg qd administered for 35-42 days with subcutaneous enoxaparin 40 mg qd...
: Primary myelofibrosis (PMF) is a clonal hematopoietic stem cell disorder characterized by fibrosis of the marrow cavity, marked megakaryocyte atypia and progressive cytopenias. Although thrombosis predominates, bleeding is the primary manifestation in up to 20% of patients and may be life-threatening. In this report, we document restoration of megakaryocyte and platelet structure and function in PMF after allogeneic hematopoietic cell transplantation (HCT). A 59-year-old...
Unique expertise is required for the care of children, adolescents, and young adults with bleeding and clotting disorders. A number of Hemophilia Treatment Centers have developed pediatric hemostasis and thrombosis fellowship programs to facilitate subspecialty training and recruitment and retention in this field. This manuscript reviews an approach to training pediatric coagulationists including a description of current programs, sample curriculum, funding sources, and...
PURPOSE: Patients with inflammatory bowel disease (IBD) are at increased risk of postoperative venous thromboembolism (VTE) following major abdominal surgery. The pathogenesis is multifactorial and not fully understood. A combination of pathophysiology, patient and surgical risk factors increase the risk of postoperative VTE in these patients. Despite being at increased risk, IBD patients are not regularly prescribed extended pharmacological thromboprophylaxis following...
BACKGROUND: To establish which major disorders are susceptible to increased mortality following acute admissions on weekends, compared with week days, and how this may be explained.
METHODS: Cohorts based on national administrative inpatient and mortality data for 14,168,443 hospitalised patients in England and 913,068 in Wales who were admitted for 66 disorders that were associated with at least 200 deaths within 30 days of acute admission. The main outcome measure...
BACKGROUND: Venous thromboembolism (VTE) complicates several anti-cancer regimens including chemotherapy and anti-angiogenic agents. Cyclin-dependent kinase inhibitors (CDKIs) are a new approach for hormone receptor positive metastatic breast cancer (mBC). Reported VTE rates in randomized trials range from 0.6% to 5%, but these may underestimate actual rates observed in clinical practice.
OBJECTIVES: Evaluate VTE rate and its association with outcomes in CDKIs...
ICTHIC Lunchtime Symposium April 2018: Dr Marc Carrier
ICTHIC Lunchtime Symposium April 2018: Alexander Cohen
ICTHIC Lunchtime Symposium April 2018: Dr Florian Langer MD
ICTHIC Lunchtime Symposium April 2018: Dr Luis Jara-Palomares, MN, PhD
Structured Modules in CAT
Nov 21, 2016
Oct 28, 2016
Oct 27, 2016
Sep 29, 2016
This website is intended to provide non-promotional, educational information to an international healthcare professional audience only.
You have indicated that you are not a healthcare professional and therefore, do not have access to this site.Please click here to continue browsing
This website is owned by LEO Pharma.
Cookies by themselves cannot be used to discover the identity of the user, and they do not in any way damage your computer.
We use a Google Analytics cookie, further information can be seen here:: Google Analytics Cookie Usage
The browsers of most computers, smartphones and other web-enabled devices are typically set up to accept cookies. If you wish to amend your cookie preferences for this site or any other websites, you can do this through your browser settings. Your browser's 'help' function will tell you how to do this.
However, please remember that cookies are often used to enable and improve certain functions on our site. If you therefore choose to disable the cookies that we use, this may impact your experience while on www.cathrombosis.com, for example, you may not be able to visit certain areas of the site and you may not receive personalised information.
If you use different devices to view and access the site (e.g. your computer, smartphone, tablet etc.) you will need to ensure that each browser on each device is adjusted to suit your cookie preferences.
For more information on how to disable cookies, visit www.allaboutcookies.org